Advantages of the AMDL-ELISA DR-70 (FDP) assay over carcinoembryonic antigen (CEA) for monitoring colorectal cancer patients.
The DR-70 (FDP) test was the first cancer test cleared by USFDA for monitoring colorectal cancer (CRC) since Carcinoembryonic Antigen (CEA) in 1982. Conservatively, 50% of biopsy-positive CRC patients have negative CEA values. DR-70 and CEA values were compared for 113 CRC monitoring patients. Total concordance rates for DR-70 and CEA were 0.665 and 0.686, respectively. CRC patient pairs were grouped based on their CEA value to deduce DR-70's effectiveness at monitoring patients with low CEA values. DR-70 had 12% to 100% greater positive concordance rates than CEA in this group. DR-70 is a welcome new option for CRC patients.
Small-Howard
Andrea L
AL
AMDL Inc., Tustin, CA 92780, USA. asmallhoward@amdl.com
Harris
Holden
H
D002272:Carcinoembryonic Antigen / Q000097:blood*; D015179:Colorectal Neoplasms / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D006801:Humans; D008991:Monitoring, Physiologic / Q000379:methods*; D012189:Retrospective Studies
D002272:Carcinoembryonic Antigen
Jpn J Clin Oncol. 2001 Aug;31(8):388-94
11574632
Annu Rev Cell Biol. 1988;4:93-126
3143380
Mol Pathol. 2000 Dec;53(6):307-12
11193049
Blood Coagul Fibrinolysis. 2004 Jan;15(1):9-13
15166937
Am J Hematol. 2002 Apr;69(4):247-54
11921018
Biol Chem Hoppe Seyler. 1992 Jul;373(7):611-22
1515091
Jpn J Clin Oncol. 2000 Jan;30(1):12-6
10770562
Gastroenterology. 2005 Oct;129(4):1151-62
16230069
Aliment Pharmacol Ther. 2004 Nov 1;20(9):983-7
15521846
Ann N Y Acad Sci. 1992 Dec 4;667:101-11
1309029
Histopathology. 2002 May;40(5):472-9
12010368
Br J Cancer. 2002 Feb 1;86(3):389-95
11875705
Anticancer Res. 1994 May-Jun;14(3B):1409-12
8067714
Dis Colon Rectum. 1998 Sep;41(9):1127-33
9749496
J Natl Cancer Inst. 1999 May 19;91(10):869-74
10340907
Cancer. 1978 Sep;42(3 Suppl):1412-8
361200
Acta Oncol. 2004;43(8):770-1
15764225
Biochem Soc Trans. 1994 Feb;22(1):18S
7515829
Br J Oral Maxillofac Surg. 2005 Dec;43(6):513-5
16188352
Int J Cancer. 2005 May 1;114(5):702-12
15609318
Blood Coagul Fibrinolysis. 2001 Jan;12(1):51-8
11229827
J Clin Oncol. 2000 Feb;18(3):600-8
10653875
Oncogene. 1997 May 29;14(21):2563-73
9191056
Cancer Res. 1991 Sep 1;51(17):4549-56
1873799
Lab Invest. 1987 Dec;57(6):673-86
2447383
Cancer. 2004 Jul 1;101(1):77-82
15221991
Clin Chem. 1980 Jul;26(8):1213-20
7389095
Ann Clin Biochem. 1998 Jan;35 ( Pt 1):99-103
9463746
Dis Colon Rectum. 1996 Oct;39(10):1102-6
8831523
Hum Pathol. 1987 Mar;18(3):275-84
3546076
Dis Colon Rectum. 1994 Mar;37(3):272-7
8137675
Chest. 2000 Oct;118(4):948-51
11035661
Immunol Res. 2000;21(2-3):289-92
10852129
Eur J Surg Oncol. 2002 Jun;28(4):418-23
12099653
Surg Oncol Clin N Am. 2006 Jan;15(1):175-93, viii
16389157
J Lab Clin Med. 2004 Apr;143(4):241-54
15085083
Mol Med. 2004 Jan-Jun;10(1-6):6-11
15502877
Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4083-8
15217943
Biochem Biophys Res Commun. 2005 Apr 1;329(1):237-45
15721299
Oncogene. 2005 Dec 15;24(56):8240-51
16091733
Cancer. 2002 Oct 15;95(8):1618-28
12365008
Respir Med. 2004 Feb;98(2):93-8
14971870
World J Gastroenterol. 2004 Mar 15;10(6):922-3
15040048
Surg Oncol Clin N Am. 2006 Jan;15(1):21-37
16389148
J Pathol. 1992 Sep;168(1):47-53
1280677
Br J Cancer. 2005 Feb 14;92(3):430-3
15685236
J Am Coll Surg. 2006 Jan;202(1):139-45
16377507
Med Oncol. 2007;24(2):219-25
17848747
Thromb Haemost. 2007 Jan;97(1):119-23
17200778
Hepatogastroenterology. 1983 Aug;30(4):140-2
6629305
J Immunoassay. 1998 Feb;19(1):63-72
9530612
Thromb Haemost. 1998 Dec;80(6):894-8
9869156
Cancer. 2000 Jan 15;88(2):295-301
10640960
Surg Today. 1998;28(4):373-8
9590700
J Lab Clin Med. 2006 Jan;147(1):27-35
16443002
Blood. 1991 Jul 15;78(2):479-87
1648983
Cancer. 2003 Jun 15;97(12):3044-52
12784340
Cancer Metastasis Rev. 1984;3(2):99-114
6386144
J Surg Oncol. 1985 Feb;28(2):156-9
3918217